Chiasma (CHMA) Has Enough Cash To Reach Profitability - Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Chiasma Reports Fourth Quarter and Year End 2015 Results
March 14, 2016 4:01 PM EDTInitiates Pivotal EU Phase 3 Trial
Expands Organization in Advance of PDUFA Date
Provides Operating Expense Guidance for 2016
NEWTON, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a late-stage biopharmaceutical company developing Mycapssa (octreotide) capsules, an investigational new oral drug for the maintenance therapy of adult patients with the orphan disease acromegaly, today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2015.
Chiasma made significant progress from a clinical, regulatory, financial and organizational standpoint in... More
